Related Experiment Video
Updated: May 29, 2025
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Treatable Traits-Based Pharmacologic Treatment of Sleep Apnea
1Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 424, Gothenburg 405 30, Sweden.
Abstract:
Obstructive sleep apnea (OSA) is a heterogeneous condition characterized by diverse endotypic traits and clinical phenotypes. A recent randomized controlled trial evaluating a glucagon-like peptide-1 receptor agonist showed promising results, potentially making it the first on-label drug treatment for OSA. Phase II/III clinical trials investigating combinations of noradrenergic and antimuscarinic agents, as well as carbonic anhydrase inhibitors, are ongoing. Future drug treatments for OSA, either as monotherapy or combined with other treatment modalities, will be personalized and based on treatable traits to address underlying mechanisms, comorbid conditions, and patient-reported outcome measures.
Insights
New drug treatments for obstructive sleep apnea (OSA) are emerging, with a glucagon-like peptide-1 receptor agonist showing promise. Future OSA therapies will be personalized based on individual traits and patient outcomes.
Area of Science:
- Sleep Medicine
- Pharmacology
- Respiratory Medicine
Background:
- Obstructive sleep apnea (OSA) is a complex condition with varied patient presentations.
- Current OSA management often relies on non-pharmacological interventions.
Purpose of the Study:
- To review the emerging landscape of pharmacotherapy for obstructive sleep apnea.
- To highlight the potential of novel drug classes in OSA treatment.
Main Methods:
- Review of recent clinical trials and research findings.
- Analysis of ongoing Phase II/III clinical trials for OSA pharmacotherapies.
Main Results:
- A glucagon-like peptide-1 receptor agonist demonstrated promising efficacy in a recent trial.
- Multiple drug classes, including noradrenergic and antimuscarinic agents and carbonic anhydrase inhibitors, are under investigation.
Conclusions:
- Pharmacological interventions are poised to become a significant treatment modality for OSA.
- Future OSA drug treatments will likely be personalized, targeting specific patient endotypes and comorbidities.
- Treatment personalization will incorporate patient-reported outcomes for comprehensive care.
Related Concept Videos
01:19Management of Insomnia
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:07Narcolepsy
01:17Sleepwalking and Sleep Talking
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...